The first example of a brand new therapeutic modality for the management of recurrent migraine has been approved for marketing by the US FDA. Although the safety profile of this approach and others that will follow has not yet been fully elucidated, it is likely that the distinctly different mechanism of action will be the basis for a significant point of difference. More here: